| A phase II trial of vinorelbine and thiotepa in metastatic breast cancer. | |
| | |
MedLine Citation:
|
PMID: 7786825 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: Vinorelbine as single-agent has achieved an overall response rate of > 20% as second-line treatment and 40%-50% as first-line treatment. The aim of this study was to evaluate the activity and toxicity of the combination of vinorelbine and thiotepa as second-line treatment in patients with metastatic breast cancer. PATIENTS AND METHODS: Thirty-three patients (31: anthracycline-based chemotherapy, 16: high-dose epirubicin) were given vinorelbine 30 mg/m2 and thiotepa 12 mg/m2 d 1 and 8 every 21 days. RESULTS: Among the 32 evaluable patients two complete responses and seven partial responses were observed, for an overall response rate of 28% (C.I. 12-44). The median duration of response was 9 months and the median time to progression 6 months. Significant toxicity was primarily leukopenia (72%); anemia was also frequent (48%) as well as local phlebitis (39%). CONCLUSION: The present study has shown this combination to be active as second-line treatment, and its toxic effects have been well tolerated. It should be considered a reasonable option for patients with metastatic disease who have already been treated with anthracyclines. |
| | |
Authors:
|
A Fabi; R Tonachella; A Savarese; S Cirulli; S Tomao; E Conte; F Cognetti |
Related Documents
:
|
20740185 - Low-dose fulvestrant maintained long-term complete remission after poor response to pre... 22150115 - Submandibular gland-sparing intensity modulated radiotherapy in the treatment of head a... 18712595 - Weekly epirubicin in the treatment of gestational breast cancer (gbc). 6846245 - Phase ii study of maytansine in the treatment of advanced or recurrent adenocarcinoma o... 22720895 - Selective internal radiation therapy of hepatocellular carcinoma: potential hepatopulmo... 9482685 - Low acute toxicity of radiotherapy and radiochemotherapy in patients with cancer of the... |
Publication Detail:
|
Type: Clinical Trial; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Annals of oncology : official journal of the European Society for Medical Oncology / ESMO Volume: 6 ISSN: 0923-7534 ISO Abbreviation: Ann. Oncol. Publication Date: 1995 Feb |
Date Detail:
|
Created Date: 1995-07-27 Completed Date: 1995-07-27 Revised Date: 2006-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 9007735 Medline TA: Ann Oncol Country: NETHERLANDS |
Other Details:
|
Languages: eng Pagination: 187-9 Citation Subset: IM |
Affiliation:
|
Servizio di Oncologia Medica, Istituto Regina Elena per lo Studio e la Cura dei Tumori, Rome, Italy. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Antineoplastic Combined Chemotherapy Protocols / adverse effects, therapeutic use* Bone Marrow Diseases / chemically induced Breast Neoplasms / drug therapy*, mortality, pathology Drug Resistance Female Humans Life Tables Menopause Middle Aged Neoplasm Metastasis Phlebitis / chemically induced Remission Induction Salvage Therapy Survival Analysis Thiotepa / administration & dosage, adverse effects Treatment Outcome Vinblastine / administration & dosage, adverse effects, analogs & derivatives |
| Chemical | |
Reg. No./Substance:
|
52-24-4/Thiotepa; 71486-22-1/vinorelbine; 865-21-4/Vinblastine |
| Comments/Corrections | |
Comment In:
|
Ann Oncol. 1995 Feb;6(2):105-7
[PMID:
7786816
]
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: ChlVPP therapy for Hodgkin's disease: experience of 960 patients. The International ChlVPP Treatment...
Next Document: Phase I study of weekly high-dose cisplatin combined with long-term oral etoposide in advanced solid...